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Introduction
Tissue remodeling responses are prominent features of
inflammatory disorders of the airway and parenchyma
of the lung. These responses are readily apparent in
chronic obstructive pulmonary disease (COPD), asth-
ma, and interstitial lung diseases: in which remodeling
causes the alveolar septal destruction and changes in
compliance that are characteristic of pulmonary emphy-
sema (1), the subepithelial fibrosis, mucus metaplasia,
and other structural alterations seen in asthmatic air-
way remodeling (2), and the pulmonary fibrosis that
characterizes the interstitial disorders (3). Elevated lev-
els of matrix metalloproteinases (MMPs) have been
noted in patients with these disorders (4–12). In addi-
tion, studies from our laboratories and others demon-
strated that MMP-12 plays an essential role in the
pathogenesis of cigarette smoke–induced emphysema
in mice (13) and that pretreatment with broad-spec-
trum MMP antagonists decreases the inflammation
and airway hyperresponsiveness in murine models of
asthma and the fibrosis in murine models of interstitial
lung disorders (14, 15). Surprisingly, little else is known
about the roles that individual MMPs play in the patho-
genesis of these important pulmonary disorders.
IL-13 is a pleiotropic 12-kDa product of a gene on
chromosome 5 at q31 that is produced in large quan-
tities by Th2 cells and in lesser quantities by Th1 cells.
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IL-13 potently stimulates eosinophilic and lymphocytic inflammation and alveolar remodeling
in the lung, effects that depend on the induction of various matrix metalloproteinases (MMPs).
Here, we compared the remodeling and inflammatory effects of an IL-13 transgene in lungs of
wild-type, MMP-9–deficient, or MMP-12–deficient mice. IL-13–induced alveolar enlargement,
lung enlargement, compliance alterations, and respiratory failure and death were markedly
decreased in the absence of MMP-9 or MMP-12. Moreover, IL-13 potently induced MMPs-2, -12,
-13, and -14 in the absence of MMP-9, while induction of MMPs-2, -9, -13, and -14 by IL-13 was
diminished in the absence of MMP-12. A deficiency in MMP-9 did not alter eosinophil,
macrophage, or lymphocyte recovery, but increased the recovery of total leukocytes and neu-
trophils in bronchoalveolar lavage (BAL) fluids from IL-13 transgenic mice. In contrast, a defi-
ciency in MMP-12 decreased the recovery of leukocytes, eosinophils, and macrophages, but not
lymphocytes or neutrophils. These studies demonstrate that IL-13 acts via MMPs-9 and -12 to
induce alveolar remodeling, respiratory failure, and death and that IL-13 induction of MMPs-2,
-9, -13, and -14 is mediated at least partially by an MMP-12–dependent pathway. The also demon-
strate that MMPs-9 and -12 play different roles in the generation of IL-13–induced inflammation,
with MMP-9 inhibiting neutrophil accumulation and MMP-12 contributing to the accumulation
of eosinophils and macrophages.
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Exaggerated IL-13 production has been documented
in a variety of diseases characterized by inflammation
and remodeling, including asthma, idiopathic pul-
monary fibrosis, scleroderma, nodular sclerosing
Hodgkin disease, and type II tissue granulomatous
inflammation (16–24). The inflammatory and remod-
eling effector properties of IL-13 can be appreciated in
studies from our laboratory that demonstrated that
the constitutive and/or inducible transgenic overex-
pression of IL-13 in the murine lung generates a strik-
ing phenotype with eosinophil-, lymphocyte-, and
macrophage-rich inflammation, airway remodeling
with subepithelial fibrosis, parenchymal fibrosis,
mucus metaplasia, and striking increases in alveolar
size, lung size, and pulmonary compliance (25, 26). 
IL-13 is a potent inducer and activator of a variety of
MMPs, including MMP-9 and MMP-12, in both of
these transgenic modeling systems (25, 26). Previous
studies from our laboratory demonstrated that 
MMP-9 plays a key role in the generation of 
IL-13–induced tissue fibrosis by contributing to the
activation of latent TGF-β (27). The contributions that
MMP-9 and MMP-12 make to the pathogenesis of the
inflammatory and alveolar remodeling effects of IL-13
have, however, not been defined.
We hypothesized that MMP-9 and MMP-12 play
important and distinct roles in the generation of 
IL-13–induced tissue phenotypes. To test this hypoth-
esis, we compared the inflammatory and remodeling
responses induced by IL-13 in mice with wild-type (+/+)
or null (–/–) MMP-9 or MMP-12 loci. These studies
demonstrate that IL-13 induces alveolar enlargement,
lung enlargement, compliance alterations, respiratory
failure, and death via a, MMP-9– and MMP-12–
dependent mechanism(s), and that IL-13 induction of
MMPs-2, -9, -13, and -14 is mediated, in part, by an
MMP-12–dependent pathway(s). They also demon-
strate that MMP-9 and MMP-12 play different roles in
the generation of IL-13–induced inflammation, with
MMP-9 inhibiting neutrophil accumulation and
MMP-12 making a crucial contribution to the accu-
mulation of eosinophils and macrophages.
Methods
Transgenic mice. Two types of transgenic mice were gener-
ated in our laboratories and used in these studies. Both
use the Clara cell 10-kDa protein (CC10) promoter to tar-
get transgene expression to the lung. In the CC10-IL-13
mice, the CC10 promoter drives the expression of murine
IL-13 in a constitutive fashion. To allow IL-13 to be
expressed in a temporally regulated fashion, CC10-rtTA-
IL-13 mice were used. In these dual transgenic mice, the
IL-13 transgene is activated by adding doxycycline (dox)
to the animal’s drinking water. In both transgenic sys-
tems, IL-13 caused a mononuclear cell– and eosinophil-
rich tissue inflammatory response, alveolar enlargement,
subepithelial and parenchymal fibrosis, and mucus 
metaplasia, as previously described (25, 26). In keeping 
with the chronic nature of the IL-13 production in the 
CC10-IL-13 mice, the phenotype of these animals pro-
gressed most rapidly. These animals died prematurely
from an inflammatory-fibrodestructive lung disorder.
The MMP-9–/– mice and the MMP-12–/– mice were
generated as described previously by our laboratories
(13, 28) and bred with C57BL/6 mice. CC10-IL-13 and
CC10-rtTA-IL-13 mice with wild-type and null MMP
loci were generated by breeding of the IL-13–overex-
pressing mice with the MMP–/– animals. As previously
described (25, 26, 29), PCR was used to define the
transgenic status of all offspring, using primers that
detected rtTA and/or the junction region of our
murine IL-13–human growth hormone construct. The
MMP-9 loci were evaluated using PCR primers that
determined whether exon 2 was intact and/or whether
NEO inserts could be detected (28). The MMP-12 loci
were evaluated by PCR using primers that were located
in exon 1 (5′-CTG CCT GTG GGG CTG CTC CCAT-3′) and
exon 3 (5′-ATC CTC ACG CTT CAT GTC CG-3′).
Dox water administration. In experiments performed
with CC10-rtTA-IL-13 transgene+ animals and their lit-
termate controls, all animals were maintained on nor-
mal water until they were 1 month old. They were then
randomized to receive either normal water or water
with dox (500 mg/ml in 40% sucrose) for the duration
of the experiment.
Bronchoalveolar lavage and lung volume and compliance
assessments. Lung inflammation was assessed by bron-
choalveolar lavage (BAL), and lung volume and com-
pliance measurements were made using pressure fix-
ation and volume displacement as previously
described (25, 26, 30, 31).
Histologic morphometric and mucus evaluations. Mice were
anesthetized, a sternotomy was performed, right heart
perfusion with PBS was undertaken, and the heart and
lungs were removed. The lungs were then inflated with
Streck solution to a fixed pressure of 25 cm, embedded
in paraffin, sectioned at 5 µm, and stained. Hema-
toxylin and eosin (H&E), trichrome, and periodic acid-
Schiff with diastase (D-PAS) stains were performed in
the Research Histology Laboratory of the Department
of Pathology at Yale University School of Medicine.
Alveolar size was estimated from the mean chord
length of the airspace as previously described by our
laboratory (25, 31). The histologic mucus index (HMI),
a measurement of the percentage of D-PAS+ epithelial
cells per unit of airway basement membrane, was cal-
culated as previously described by our laboratory (25).
mRNA analysis. mRNA levels were evaluated by 
RT-PCR analysis, using whole-lung RNA and primer
pairs previously described by our laboratory (25). 
β-Actin was used as an internal standard. Amplified
PCR products were detected using ethidium bromide
gel electrophoresis, quantitated electronically, and con-
firmed by nucleotide sequencing.
Quantification of IL-13, chemokines, and TGF-β1. BAL 
IL-13, macrophage inflammatory protein-2 (MIP-2),
KC, and monocyte chemoattractant protein-1 (MCP-1)
were quantitated using commercial ELISA kits (R&D
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Systems Inc., Minneapolis, Minnesota, USA) according
to the manufacturer’s instructions. Total and bioactive
TGF-β1 were evaluated using mink lung epithelial cells
permanently transfected with a construct containing
the TGF-β1–responsive plasminogen activator
inhibitor-1 promoter fused to the luciferase reporter
gene (a gift from John Munger, New York University
Medical Center, New York, New York, USA). Assays
were performed with untreated and acid-treated BAL
fluids incubated with control antibodies or antibodies
that neutralize TGF-β1, as previously described (27).
Collagen evaluation. Lung collagen content was evalu-
ated using trichrome evaluations, Sircol Collagen
Assays (Biocolor Ltd., Belfast, United Kingdom), and
Picosirius red staining as previously described (27).
In situ hybridization. To localize MMP-2 and MMP-14,
in situ hybridization was used. The methods that 
were employed have been described previously by our 
laboratory (27).
Western blot analysis. Transgene– and transgene+ CC10-
rtTA-IL-13 mice with wild-type and null MMP loci were
randomized to normal water or dox water at 1 month
of age and maintained on this regimen for an addi-
tional month. Their lungs were then removed, and
lysates were prepared using lysis buffer supplemented
with antiproteases (20 mM Tris [pH 7.5], 150 mM
NaCl, 1 mM EDTA, 1% Triton, 2.5 mM Na phosphate,
50 µM Na molybdate, 1 mM β-glyceralphosphate, 1
µM Na vanadate, 1 µg/ml leupeptin, 10 µg/ml apro-
tinin, 1 mM PMSF). Equal concentrations (10 µg) of
protein from each lung were then loaded and run on
7% stacking and 12% resolving SDS-PAGE gels. Trans-
fer to Immobilon (Millipore Inc., Bedford, Massachu-
setts, USA) PVDF membranes was accomplished as pre-
viously described (27). Protein detection was
accomplished with a Super Signal West Femto Maxi-
mum kit (Pierce Chemical Co., Rockford, Illinois, USA)
according to the manufacturer’s instructions. Poly-
clonal goat antisera against MMP-2, MMP-9, MMP-13,
and MMP-14 (Santa Cruz Biotechnology Inc., Santa
Cruz, California, USA) were the primary antibodies
that were employed. The secondary antibody was a
mouse anti-goat IgG conjugated to horseradish perox-
idase (Santa Cruz Biotechnology Inc.).
Statistics. Normally distributed data are expressed as
means ± SEM and were assessed for significance by Stu-
dent’s t test or ANOVA as appropriate. Data that were
not normally distributed were assessed for significance
using the Wilcoxon rank sum test.
Results
Role(s) of MMPs in IL-13–induced alterations in lung volume
and alveolar size. To determine whether MMP-9 or
MMP-12 played an important role in the pathogenesis
of IL-13–induced alterations in lung and alveolar size,
we compared these parameters in CC10-rtTA-IL-13
transgene+ mice with wild-type and null MMP-9 or
MMP-12 loci. Lung size, lung volume, and alveolar size
were similar in lungs from MMP-9–/– mice, MMP-12–/–
mice, and wild-type littermate controls (Figures 1 and
2). In accord with previous observations (25), these
parameters were not altered by dox administration
(data not shown). Dox induction of IL-13 production
in transgene+/MMP+/+ mice did, however, induce an
impressive increase in all three of these parameters (Fig-
ures 1 and 2). In contrast, IL-13 did not have the same
effect in mice that were deficient in either of these
MMPs. After 1 or 2 months of dox administration, the
size and volume of lungs from CC10-rtTA-IL-13+/
MMP-9–/– mice and CC10-rtTA-IL-13+/MMP-12–/– mice
were significantly smaller than those of lungs from
CC10-rtTA-IL-13+ animals with wild-type MMP loci
(Figures 1 and 2 and data not shown). Alveolar size was
also significantly decreased in dox-treated CC10-rtTA-
IL-13 transgene+ animals with null MMP-9 or MMP-12
loci. This was readily apparent morphometrically
where the mean alveolar chord length in CC10-rtTA-
IL-13+/MMP-9–/– mice and CC10-rtTA-IL-13+/
MMP-12–/– mice was significantly smaller than the
chord length in lungs from CC10-rtTA-IL-13+/MMP+/+
animals (Figure 2, b and d). Similar decreases in lung
volume and alveolar size were seen in comparisons of
CC10-IL-13+/MMP+/+ mice and CC10-IL-13+ mice with
null mutations of MMP-9 or MMP-12 (data not
shown). With both transgenic systems, the decrease in
alveolar size in IL-13–producing mice with null versus
wild-type MMP-9 or MMP-12 loci was also readily
apparent in comparisons of H&E-stained tissue sec-
tions (Figure 3). When viewed in combination, these
studies demonstrate that MMP-9 and MMP-12 play
similar critical roles in the pathogenesis of IL-13–
induced alveolar and lung enlargement.
Role(s) of MMPs in IL-13–induced alterations in lung com-
pliance. Enhanced pulmonary compliance with
decreased elastic recoil is characteristic of COPD (1)
and asthma (32) and prominent in lungs from IL-13–
producing transgenic mice (25). To see whether 
MMP-9 or MMP-12 played a role in the generation of
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Figure 1
Effect of MMP-9 and MMP-12 deficiency on IL-3–induced alterations
in lung size. CC10-rtTA-IL-13 transgene– and transgene+ mice with
wild-type and null MMP-9 (top) or MMP-12 (bottom) loci were gen-
erated and placed on dox water at 1 month of age. They were main-
tained on this regimen for an additional month, at which time their
lungs were removed, fixed to pressure, and photographed.
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this abnormality, we compared lungs from littermate
CC10-rtTA-IL-13 transgene+ mice that were wild-type
and null at these MMP loci. As previously reported (25),
lungs from CC10-rtTA-IL-13+/MMP+/+ mice were more
compliant than lungs from transgene– controls (Table
1). Interestingly, lungs from CC10-rtTA-IL-13+/
MMP-9–/– mice were less compliant than lungs from
CC10-rtTA-IL-13+/MMP-9+/+ animals (Table 1). Simi-
larly, lungs from CC10-rtTA-IL-13+/MMP-12–/– mice
were also less compliant than lungs from CC10-rtTA-
IL-13+/MMP+/+ controls (Table 1). These studies
demonstrate that MMP-9 and MMP-12 play similar
critical roles in the pathogenesis of the IL-13–induced
pulmonary compliance alterations in these animals.
Role(s) of MMPs in IL-13–induced mucus metaplasia. Stud-
ies were next undertaken to determine whether MMP-9
or MMP-12 played an important role in the pathogen-
esis of IL-13–induced mucus metaplasia. As previously
described (25), D-PAS–staining cells were not appreci-
ated in airways from transgene– mice on normal or dox
water, low-level mucus production was seen in CC10-
rtTA-IL-13+/MMP+/+ mice on normal water (HMI = 
10.1 ± 3), and prominent mucus production was seen in
CC10-rtTA-IL-13+/MMP+/+ mice on dox water for 1
month (HMI = 53.1 ± 6). In addition, IL-13 induced
epithelial hypertrophy and stimulated Muc5ac, Muc-4,
and Muc-1 mRNA accumulation in lungs from these
animals (data not shown). Importantly, similar levels of
mucus metaplasia were seen in CC10-rtTA-IL-13 
transgene+ mice with null mutations of MMP-9 
(HMI = 48.9 ± 9) or MMP-12 (HMI = 50.1 ± 6) (P > 0.5
vs. dox-treated CC10-rtTA-IL-13+/MMP+/+ mice for
both comparisons). In addition, IL-13 caused epithelial
hypertrophy and stimulated mucin gene expression in
the presence and absence of MMP-9 or MMP-12 (data
not shown). Thus, neither MMP-9 nor MMP-12 played
a critical role in the pathogenesis of IL-13–induced
mucus metaplasia.
Role(s) of MMP-12 in IL-13–induced tissue fibrosis. Previ-
ous studies from our laboratory demonstrated that 
IL-13 is a potent stimulator of tissue fibrosis and that
this tissue response is mediated, to a great extent, by
the ability of IL-13 to stimulate the production of 
TGF-β1 (27). Studies were thus undertaken to deter-
mine whether IL-13–induced TGF-β1 elaboration and
fibrosis were similarly altered in the absence of 
MMP-12. In these experiments, CC10-rtTA-IL-13 mice
were used to evaluate TGF-β1 production at time
points before subepithelial fibrosis could be appreciat-
ed, and CC10-IL-13 mice were used to evaluate TGF-β
levels at later time points when frank fibrosis was
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Figure 2
Effects of MMP deficiency on IL-13–induced alterations in lung vol-
ume and alveolar size. CC10-rtTA-IL-13 transgene– and transgene+
mice with wild-type and null MMP-9 or MMP-12 loci were generat-
ed and placed on dox water at 1 month of age. They were maintained
on this regimen for an additional month, at which time their lungs
were removed and fixed to pressure. Lung volume (a and c) and alve-
olar size (chord length; b and d) were assessed as described in Meth-
ods. The noted values represent the mean ± SEM of a minimum of
five animals in each group (*P < 0.01).
Figure 3
Alveolar effects of MMP-9 and MMP-12 deficiency. CC10-rtTA-IL-13
transgene– and transgene+ mice with wild-type and null MMP-9 (a)
or MMP-12 (b) loci were generated and placed on dox water at 1
month of age. They were maintained on this regimen for an addi-
tional month, at which time their lungs were removed, fixed to pres-
sure, and evaluated after H&E staining.
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apparent. At the early (2- to 4-week) time points, IL-13
was a modest stimulator of TGF-β1 elaboration in
MMP-12+/+ mice and this induction was decreased in
IL-13+/MMP-12–/– animals (Figure 4). In contrast, at
later time points (3.0–4 months), these differences
could no longer be appreciated. At these time points,
similar levels of tissue fibrosis and TGF-β1 induction
were noted in IL-13–overexpressing mice with wild-type
and null MMP-12 loci (Figure 4).
Roles of MMP-9 and MMP-12 in IL-13–induced respiratory
failure and death. As previously described (33), CC10-
IL-13 mice experience progressive fibrodestructive lung
alterations and die prematurely from respiratory failure.
To determine whether MMP-9 or MMP-12 plays a role
in these alterations, we compared the survival of CC10-
IL-13 mice with wild-type and null MMP-9 or 
MMP-12 loci. The CC10-IL-13+/MMP+/+ mice started to
die when they were 90–100 days old, and 100% were
dead by the time they were 144 days old. As can be seen
in Figure 5, a deficiency of MMP-9 improved the sur-
vival of these animals. Overall, CC10-IL-13+/MMP-9–/–
mice had a mean survival of 198 ± 14 days. In addition,
25% of these animals lived for more than 200 days 
(P < 0.01). Similarly, a deficiency of MMP-12 also
improved the survival of the CC10-IL-13 animals, with
85% of CC10-IL-13+/MMP-12–/– animals living for more
than 220 days (Figure 5). Interestingly, similar fibrotic,
inflammatory, crystalline, and alveolar filling respons-
es were noted in the terminal phases of the disease
regardless of the status of the MMP-9 or the MMP-12
loci (Figure 5 and data not shown). Thus, MMP-9 and
MMP-12 play important roles in the pathogenesis of 
IL-13–induced respiratory failure and death.
Effect of MMP deficiency on IL-13 elaboration. MMP defi-
ciency could modify IL-13–induced phenotypes by
altering IL-13 production or by modifying IL-13 effec-
tor function(s). To determine whether MMP-9 or
MMP-12 regulated CC10 promoter–driven IL-13 elab-
oration, we compared the levels of BAL IL-13 in CC10-
rtTA-IL-13 transgene+ mice with wild-type and null
MMP-9 or MMP-12 loci that had been on dox water for
identical intervals. At all time points, similar levels of
IL-13 were noted (data not shown). Thus, MMP-9 and
MMP-12 alter IL-13–induced phenotypes by modifying
IL-13 effector pathways.
Effects of MMP deficiency on IL-13 induction of lung proteas-
es. The studies noted above demonstrate that MMP-9
and MMP-12 play similar roles in the pathogenesis of 
IL-13–induced alveolar remodeling in the lung. We rea-
soned that this similarity could be due to the participa-
tion of both of these MMPs in the same MMP path-
way(s) that mediates IL-13–induced lung proteolysis. To
test this hypothesis, we compared the levels of MMP
mRNA and protein in IL-13 transgene– and transgene+
mice with wild-type, MMP-9–/–, and MMP-12–/– loci. In
transgene– mice, the levels of mRNA encoding MMP-2
and MMP-14 were slightly increased and the levels of
mRNA encoding MMP-12 and MMP-13 were similar in
MMP-9+/+ and MMP-9–/– animals on normal water or
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Table 1
IL-13-induced compliance alterations: role(s) of MMP-9 and 
MMP-12
Transgene MMP Volume (ml) Compliance (ml/cm)
MMP-9
– +/+ 1.6 0.064 ± 0.001
– –/– 1.55 0.062 ± 0.003
+ +/+ 2.7 0.108 ± 0.040
+ –/– 1.85 0.074 ± 0.003A
MMP-12
– +/+ 1.45 0.058 ± 0.001
– –/– 1.60 0.065 ± 0.002
+ +/+ 3.2 0.128 ± 0.050
+ –/– 2.2 0.088 ± 0.002A
One-month-old CC10-rtTA-IL-13 mice with wild-type and null MMP-9 or
MMP-12 loci were treated with dox water for 4 weeks. Lung volumes and stat-
ic compliance were then assessed via volume displacement after pressure (25
cm) fixation. The noted values represent the mean ± SEM of a minimum of
five animals (AP < 0.05 vs. transgene+/MMP+/+ mice).
Figure 4
Effects of MMP-12 on IL-13–induced TGF-β1 bioactivity and tissue
fibrosis. (a) Transgene– and transgene+ CC10-rtTA-IL-13 mice were
placed on dox water for 4 weeks. BAL fluids were then obtained and
the levels of bioactive (striped bars) and total (black bars) TGF-β1
were assessed using mink lung epithelial cells as described in Meth-
ods. *P < 0.05. (b) BAL fluids were obtained from 3-month-old
CC10-IL-13 transgene– and transgene+ mice, and the levels of bioac-
tive and total TGF-β1 were assessed using mink lung epithelial cells
as described in Methods. (c) Trichrome stains are used to evaluate
the subepithelial fibrosis in lungs from 3-month-old CC10-IL-13
transgene– and transgene+ mice with wild-type and null MMP-12 loci.
Downloaded on June  3, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/14136
dox water (Figure 6a and data not shown). Similarly, the
levels of mRNA encoding MMP-2, MMP-9, MMP-13,
and MMP-14 were comparable in comparisons of 
MMP-12+/+ and MMP-12–/– animals (Figure 6b
and data not shown). In accord with previous
studies from our laboratory (25), the levels of
mRNA encoding MMPs-2, -9, -12, -13, and -14
were increased in dox-treated IL-13 transgene+
mice with wild-type MMP loci (Figure 6, a and b).
Similar levels of mRNA encoding MMPs-2, -12, 
-13, and -14 were seen in IL-13–producing mice
with wild-type and null MMP-9 loci (Figure 6a). In
contrast, the ability of IL-13 to stimulate MMP-2,
MMP-9, MMP-13, and MMP-14 mRNA accumu-
lation was decreased in the absence of MMP-12
(Figure 6b). This finding was most impressive for
MMPs-2, -13, and -14. It was less impressive for
MMP-9, whose mRNA induction was only par-
tially abrogated in the absence of MMP-12 (Figure
6b). In all cases, comparable alterations in the lev-
els of lung MMP proteins were noted on
immunoblot evaluations (Figure 6, c and d). In
addition, these findings were at least partially spe-
cific for these MMPs, as IL-13 induction of cathep-
sins H, K, L, and S were not altered in IL-13 trans-
gene+/MMP-12–/– mice (Figure 6, e and f). Impor-
tantly, in situ hybridization demonstrated that
MMP-2 and MMP-14 were made in the same cells
in transgene+ mice with wild-type and null mutant
MMP loci. Specifically, MMP-2 mRNA was detect-
ed in airway and alveolar epithelial cells and
inflammatory cells, and MMP-14 mRNA was
detected in airway and alveolar epithelial cells 
and macrophages in IL-13 transgene+ mice with 
wild-type or null MMP loci (Figure 7 and data not
shown). These studies demonstrate that a deficiency of
MMP-9 is not associated with a decrease in the basal or
IL-13–induced levels of expression of important respira-
tory MMPs. They also demonstrate that a deficiency of
MMP-12 is associated with decreased MMP induction,
because IL-13 stimulates the production of MMPs-2, -9,
-13, and -14 via a pathway(s) that is, at least partially,
MMP-12–dependent.
Effects of MMP deficiency on IL-13–induced inflammation.
Studies were next undertaken to determine whether 
IL-13 induced similar inflammatory responses in mice
with wild-type or null MMP loci. The number of cells
that were recovered and their differentials were similar
in BAL fluids from transgene– littermate controls,
MMP-9–/– mice, and MMP-12–/– mice on normal water
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Figure 5
Survival and terminal pathology of CC10-IL-13 mice and littermate
control mice with wild-type and null MMP loci. (a) The effects of
MMP-9 deficiency on survival. (b) The effects of MMP-12 deficien-
cy on survival. In a and b comparisons are made of the survival of
transgene– mice with wild-type (squares) and null (triangles) MMP
loci and transgene+ mice with wild-type (diamonds) and null (circles)
MMP loci. Each point represents the survival of a minimum of six ani-
mals. (c) The airway and parenchymal abnormalities in lungs from
near-terminal 4-month-old IL-13+/MMP-12+/+ mice and 6.5-month-
old IL-13+/MMP-12–/– mice.
Figure 6
IL-13 regulation of lung MMPs and cathepsins. CC10-rtTA-IL-13 transgene–
and transgene+ mice with wild-type and null MMP-9 loci (a, c, and e) or
MMP-12 loci (b, d, and f) were placed on dox water at 1 month of age.
After an additional month on this regimen, the levels of mRNA encoding the
noted MMPs (a and b), lung lysate MMP protein levels (c and d), and the
levels of mRNA encoding the noted cathepsins (e and f) were evaluated via
RT-PCR and immunoblot analysis as described in Methods.
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and dox water (Figures 8 and 9 and data not shown).
IL-13 production in CC10-rtTA-IL-13 mice altered
these parameters by increasing BAL cell recovery and
the percentage and recovery of lymphocytes and
eosinophils (Figures 8 and 9). MMP-9 deficiency did
not decrease the number of cells that were recovered in
BAL fluids from CC10-rtTA-IL-13 transgene+ mice. In
fact, significantly greater numbers of leukocytes were
noted in BAL fluids from dox-treated CC10-rtTA-IL-13
transgene+ mice with null versus wild-type MMP-9 loci
(Figure 8a). Differential cell counts demonstrated that
a deficiency of MMP-9 did not significantly alter 
IL-13–induced BAL macrophage, lymphocyte, and
eosinophil recovery (Figure 8) but did increase the per-
centage and recovery of BAL neutrophils (Figure 8d
and data not shown). Interestingly, these BAL alter-
ations were associated with a modest decrease in tissue
inflammation and scattered tissue neutrophils (Figure
10). In contrast, IL-13–induced BAL cellularity was
markedly decreased in CC10-rtTA-IL-13+ mice with
null MMP-12 loci (Figure 9a). Differential cell counts
demonstrated that a deficiency of MMP-12 did not
alter neutrophil or lymphocyte recovery but did
markedly diminish the recovery of macrophages and
eosinophils (Figure 9, b–e). These findings were associ-
ated with a significant decrease in tissue inflammation
(Figure 10). When viewed in combination, these 
studies demonstrate that 
MMP-9 and MMP-12 play
different roles in the patho-
genesis of IL-13–induced
inflammation, with MMP-9
inhibiting IL-13–induced
neutrophil accumulation
and MMP-12 playing a 
critical role in IL-13–
induced macrophage and
eosinophil influx.
MMP-9 regulation of neu-
trophil chemotactic cytokines.
To gain insight into mecha-
nisms that might con-
tribute to the enhanced BAL
neutrophilia in IL-13–pro-
ducing mice with null ver-
sus wild-type MMP-9 loci,
we compared the levels of
the neutrophil chemotactic
chemokines KC and MIP-2
in BAL fluids from these
animals. KC and MIP-2 were
undetectable at all time
points in BAL fluids from
wild-type and MMP-9–/–
mice that received normal
or dox water (Figure 11 and
data not shown). In con-
trast, IL-13 was a potent
inducer of both of these
chemokines. This stimulation was seen after as few as
10 days and continued to rise during the 2-month
course of dox administration. Importantly, the levels of
both of these cytokines were significantly increased in
CC10-rtTA-IL-13 transgene+ mice with null MMP-9
loci. This increase was seen after 10 days and leveled off
after 30 days of dox administration. It was also at least
partially specific for these chemokine moieties, since a
deficiency of MMP-9 decreased the levels of IL-13–
stimulated MCP-1 in the same fluids (Figure 11). A
similar decrease in MCP-1 levels was noted in BAL flu-
ids from IL-13+/MMP-12–/– animals (data not shown).
These studies demonstrate that MMP-9 is an impor-
tant and selective inhibitor of the accumulation of neu-
trophil chemotactic chemokines.
Discussion
IL-13 was originally described as an IL-4–like cytokine
with effector properties relevant to Th2 inflammation
(16, 34–36). More recent studies, from our laboratory
and others, demonstrated that IL-13 is also a power-
ful in vivo regulator of tissue remodeling with the abil-
ity to activate a variety of MMPs and cathepsins and
generate destructive and fibrotic structural responses
(22, 25–27, 37, 38). To gain additional insight into the
mechanisms of IL-13–induced inflammation and
remodeling, we took advantage of transgenic systems
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Figure 7
Localization of MMP-2 and MMP-14 mRNA. (a–f) ISH was used to localize the MMP-2 mRNA in
lungs from dox-treated CC10-rtTA-IL-13 transgene– and transgene+ mice. (a) A transgene– mouse
incubated with antisense probe. (b) A transgene– mouse incubated with sense probe. (c) A trans-
gene+ mouse incubated with antisense probe. (d) A transgene+ mouse incubated with sense probe.
(e) A transgene+ mouse incubated with antisense probe. The large and small arrows in e illustrate
inflammatory cell and epithelial cell staining, respectively. (f) A transgene+ mouse incubated with
antisense probe. The large and small arrows in f illustrate negatively staining macrophages and pos-
itively staining alveolar epithelial cells, respectively. (g–k) ISH was used to localize the MMP-14
mRNA in lungs from dox-treated CC10-rtTA-IL-13 transgene– and transgene+ mice. (g) A transgene–
mouse incubated with antisense probe. (h) A transgene– mouse incubated with sense probe. (i) A
transgene+ mouse incubated with antisense probe. (j) A transgene+ mouse incubated with sense
probe. (k) A transgene+ mouse incubated with antisense probe. The large and small arrows in k
highlight positively staining alveolar epithelial cells and macrophages, respectively.
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developed in our laboratory in which IL-13 overex-
pression causes eosinophil-, lymphocyte-, and
mononuclear cell–rich lung inflammation, MMP and
cathepsin induction, alveolar enlargement, lung
enlargement, and enhanced pulmonary compliance
(25, 26). By comparing the phenotypes induced by IL-
13 in mice with wild-type and null MMP-9 or MMP-
12 loci, we were able to define the contributions that
these MMPs make in the generation of these respons-
es. These studies demonstrate previously unappreci-
ated relationships between these MMPs and IL-13,
and between MMP-12 and other IL-13–regulated
MMPs. Specifically, they demonstrate that IL-13–
induced alveolar enlargement, lung enlargement,
compliance alterations, respiratory failure, and death
are mediated by MMP-9– and MMP-12–dependent
pathways. They also demonstrate that MMP-9 and
MMP-12 play important but distinct roles in the
pathogenesis of IL-13–induced inflammation, with
MMP-9 having prominent inhibitory effects on BAL
leukocyte accumulation and neutrophilia, and 
MMP-12 making a critical contribution to the accu-
mulation of eosinophils and macrophages. Lastly,
these studies demonstrate that, unlike MMP-9, 
MMP-12 plays an important role in MMP induction,
since MMP-12 is required for optimal IL-13 stimula-
tion of MMP-2, -9, -13, and -14 mRNA accumulation.
When viewed in combination, these studies demon-
strate that MMP-9 and MMP-12 are critical down-
stream mediators and regulators of IL-13–induced
inflammatory and alveolar remodeling responses.
They also provide crucial support for the concept that
therapies directed against these MMPs can be used to
control IL-13–induced tissue responses.
Our studies demonstrate that the ability of IL-13 to
induce alveolar enlargement, lung enlargement, com-
pliance alterations, respiratory failure, and death was
decreased in mice with null MMP-9 or MMP-12 muta-
tions when compared with wild-type controls. A variety
of effector pathway alterations can be postulated to
contribute to the similarity of these findings. These
include the decrease in the degradation of common
matrix substrates (such as type IV collagen, elastin,
aggrecan, and laminin) that would be seen in these
MMP–/– animals (39). Alternatively, a deficiency of one
or both of these MMPs could enhance the production
of antiproteases that regulate these responses. Cre-
dence for this possibility comes from studies that
demonstrate that MMP-9 can inactivate the important
pulmonary antiprotease α1-antitrypsin (40). Lastly, one
or both of these MMPs could play a critical role in the
production of other proteases that are involved in this
response. The present studies support this concept by
demonstrating, for the first time to our knowledge,
that MMP-12 is required for the optimal induction of
MMPs-2, -9, -13, and -14 by IL-13. This MMP-12
dependence was most pronounced for MMP-2 and
MMP-14. Interestingly, in situ hybridization under-
taken with lungs from transgene+ MMP+/+ and MMP–/–
mice demonstrated that MMP-2 is produced by inflam-
matory cells and airway and alveolar epithelial cells
while MMP-14 is produced by macrophages and
epithelial cells in these tissues. This demonstrates that
the decreased production of MMP-2 and MMP-14 in
lungs from transgene+ MMP-12–null mutant mice can-
not be attributed solely to the decrease in tissue inflam-
mation that is seen in comparisons of these mice and
IL-13–overexpressing MMP-12+/+ animals. Additional
experimentation will be required, however, to fully
define the mechanism(s) that is responsible for the
decreased production of these MMPs in IL-13–stimu-
lated MMP-12–deficient pulmonary tissues.
In prior studies we demonstrated that IL-13 is a potent
stimulator of pulmonary inflammation and that treat-
ment with broad-spectrum MMP antagonists inhibited
IL-13–induced BAL leukocytosis and pulmonary inflam-
mation (25, 26). Tissue inhibitors of metalloproteinases
470 The Journal of Clinical Investigation | August 2002 | Volume 110 | Number 4
Figure 8
Effect of MMP-9 deficiency on BAL leukocyte recovery. BAL was per-
formed on transgene– and transgene+ CC10-rtTA-IL-13 mice with
wild-type and null MMP-9 loci that had been randomized to normal
water or dox water. Total cell recovery (a) and the recovery of
macrophages (b), lymphocytes (c), neutrophils (d), and eosinophils
(e) are illustrated. Each value represents the mean ± SEM of a mini-
mum of four animals (*P < 0.01).
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(TIMPs), synthetic MMP antagonists, and a null muta-
tion of MMP-12 have also been demonstrated to
decrease inflammation in murine asthma, COPD, and
immune complex models (13, 15, 41). As a result we
hypothesized that MMP-9 and/or MMP-12 play key
roles in the generation of IL-13–induced tissue inflam-
mation. In accord with our hypothesis, IL-13–induced
leukocyte, macrophage, and eosinophil BAL recovery
and tissue inflammation were decreased significantly in
MMP-12–/– animals. In contrast, a deficiency of MMP-9
did not diminish IL-13–induced eosinophil and lym-
phocyte recovery and increased IL-13–induced leukocyte
and neutrophil accumulation. On superficial analysis
this would appear to be counterintuitive in light of stud-
ies that demonstrate that MMP-9 enhances neutrophil
chemotaxis in response to some chemokines (42), acti-
vates pro–IL-1β (43), increases the bioactivity of IL-8
(44), and contributes to neutrophil influx in early stages
of glomerulonephritis (39). On the other hand, MMP-9
metabolizes and inactivates neutrophilic chemokines,
including GROα (44) and mature IL-1β (43); elevated
levels of tissue neutrophils have been noted in adult
MMP-9–/– mice (42); and enhanced inflammatory cell
infiltration and IL-1α expression have been noted in
epithelial wounds in MMP-9–/– animals (45). In accord
with the documented ability of MMPs to regulate and
degrade chemokines, we noted markedly elevated levels
of the neutrophil chemotactic chemokines KC and 
MIP-2, but not the macrophage chemotactic chemokine
MCP-1, in BAL fluids from IL-13 transgenic mice with
null MMP-9 loci. We also noted that the enhanced levels
of KC and MIP-2 were not associated with comparable
increases in the mRNA encoding these moieties, demon-
strating that these events are regulated by translational
and/or posttranslational processes (S. Lanone and J.A.
Elias, unpublished observations). When viewed in com-
bination, these studies demonstrate that, in contrast to
their similar roles in IL-13–induced alveolar remodeling,
MMP-9 and MMP-12 play different roles in the patho-
genesis of IL-13–induced inflammation. Specifically,
they demonstrate that MMP-9 is a physiologic regulator
of neutrophilic responses while MMP-12 plays a critical
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Figure 9
Effect of MMP-12 deficiency on BAL leukocyte recovery. BAL was
performed on transgene– and transgene+ CC10-rtTA-IL-13 mice with
wild-type and null MMP-12 loci that had been randomized to nor-
mal water or dox water. Total cell recovery (a) and the recovery of
macrophages (b), lymphocytes (c), neutrophils (d), and eosinophils
(e) are illustrated. Each value represents the mean ± SEM of a mini-
mum of four animals (*P < 0.01).
Figure 10
Inflammation regulating effects of MMP-9 and MMP-12. CC10-
rtTA-IL-13 transgene– and transgene+ mice with wild-type and null
MMP-9 (a) or MMP-12 (b) loci were generated and placed on dox
water at 1 month of age. One month later their lungs were removed,
fixed to pressure, sectioned, stained with H&E, and evaluated via
light microscopy (×20).
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role in the generation of eosinophilic, and mono-
cyte/macrophage responses in pulmonary tissues. It is
important to point out, however, that MMPs can also
regulate tissue inflammation via a variety of other mech-
anisms, including the generation of chemotactic matrix
and compliment fragments, regulation of leukocyte pas-
sage through the vascular basement membrane, regula-
tion of cell surface cytokines and receptors, and the gen-
eration of chemokine fragments with receptor
antagonist properties (13, 41, 46). The degree to which
these mechanisms contribute to the effects of MMP-9
and MMP-12 in our models will need to be investigated.
In keeping with our prior observations (33), the present
studies demonstrate that IL-13 causes a progressive
fibrodestructive and alveolar filling lung disorder that
eventuates in respiratory failure and premature death.
They also demonstrate that survival is enhanced in trans-
gene+ animals with MMP-9– or MMP-12–null mutations.
Interestingly, when transgene+ MMP–/– animals died they
had pulmonary pathologic alterations that could not be
distinguished from those in transgene+ MMP+/+ animals.
This demonstrates that a deficiency of a single MMP
slows but does not abrogate the relentless progression of
IL-13–induced disease in this model. It also suggests that,
in the absence of MMP-9 or -12, other MMPs (or other
proteolytic enzymes) are able to “fill in” to generate the
proteolytic conditions and tissue destruction seen in the
lungs from transgene+ animals. These studies highlight
the potential utility of therapeutic interventions that tar-
get MMP-9 and/or MMP-12 in the treatment of IL-13–
induced fibrodestructive disorders. In addition, if the
MMP or other proteolytic events that are operative in the
absence of MMP-9 or -12 can be defined, these studies
suggest that an intervention(s) that simultaneously tar-
gets MMP-9 and/or -12 and these permissive proteolytic
events may be particularly useful.
Chronic inflammation is a characteristic feature 
of asthmatic airways. In most patients, eosinophils
and lymphocytes are the major inflammatory cells. 
However, in some patients, especially
those with chronic refractory disease,
impressive increases in neutrophils have
been noted (47). Via poorly understood
mechanisms, these alterations are
believed to cause the airway obstruction
and airway hyperresponsiveness that are
the most commonly assessed physiolog-
ic abnormalities in this disorder. A sig-
nificant decrease in lung elastic recoil has
also been reported in asthmatics (32, 48).
The mechanisms that are responsible for
the different types of inflammation in
asthmatic airways are poorly understood.
In addition, the mechanisms that are
responsible for the loss of elastic recoil
are among the most elusive in asthma
pathogenesis (32). A large body of data
suggests that IL-13 is a crucial mediator
in the pathogenesis of asthma (18–20).
Furthermore, numerous studies have demonstrated
that MMP-9 is found in exaggerated quantities in BAL
fluids, sputum, serum, and tissues from patients with
asthma (5–7, 49), and elevated MMP-9/TIMP-1 ratios
have been shown to correlate with therapeutic
responses to steroids in these patients (50). Surpris-
ingly, the role(s) of MMP-9 in the generation of the
asthmatic phenotype and the relationships between
MMP-9 and the anatomic, inflammatory, and physio-
logic alterations characteristic of asthma have not
been elucidated. Our studies, however, provide
insights into the roles that MMP-9 may be playing in
this disorder. Specifically, our demonstration that
MMP-9 plays an important role in IL-13–induced pro-
teolytic responses, inflammatory responses, and com-
pliance alterations in the murine lung suggests that
MMP-9 may play similar roles in the human asthmat-
ic respiratory system. Thus, the levels of MMP-9 could
influence the intensity and nature of the asthmatic
inflammatory response. In particular, elevated levels
of MMP-9 might be seen in patients with steroid-
responsive disease characterized by eosinophilic and
lymphocytic inflammation. In contrast, decreased lev-
els of MMP-9 (or MMP-9 function) might be seen in
patients with steroid-unresponsive, refractory disease
with neutrophil-rich tissue inflammation (47, 50). In
addition, genetic polymorphisms or other alterations
that cause individual-to-individual alterations in
MMP-9 production or effector function could con-
tribute to the varied natural history of this disorder. It
is also tantalizing to hypothesize that MMP-9 is a crit-
ical mediator of the loss of elastic recoil seen in the
asthmatic lung and that MMP-9 antagonists will 
eliminate this abnormality. This is a very exciting pos-
sibility, because this physiologic abnormality is
responsible for 35–55% of the reduction in maximal
expiratory flow in patients with chronic persistent
asthma (32), and treatments that address this abnor-
mality do not presently exist.
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Figure 11
Effect of MMP-9 deficiency on BAL chemokine accumulation. CC10-rtTA-IL-13
transgene– and transgene+ mice with wild-type and null MMP-9 loci were placed on
dox water at 1 month of age and maintained on dox water for an additional 10–60
days as noted. The levels of BAL KC (a), MIP-2 (b), and MCP-1 (c) protein were
assessed by ELISA. Circles, CC10-rtTA-IL-13+/MMP-9–/–; diamonds, CC10-rtTA-
IL-13+/MMP-9+/+; squares, CC10-rtTA-IL-13–/MMP-9+/+. Note that the levels of
chemokines in BAL fluids from CC10-rtTA-IL-13 transgene– mice with null and wild-
type MMP-9 loci are superimposed in these graphs. The noted values represent the
mean ± SEM of a minimum of six animals at each time point (*P < 0.01).
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The protease/antiprotease hypothesis has dominated
pathogenetic thinking in COPD for more than 35 years.
It proposes that an antiprotease “shield” protects the nor-
mal lung from locally elaborated proteases and that
emphysema is the result of an abnormal increase in pro-
teases and/or reduction in pulmonary antiproteases (1).
Inflammation has been proposed to contribute to the
pathogenesis of COPD by altering this balance. In accord
with this hypothesis, macrophage-, lymphocyte-, neu-
trophil-, and/or eosinophil-rich inflammation is a char-
acteristic feature of lungs from patients with COPD, and
epidemiologic and transgenic studies suggest that IL-13
and/or related cytokines may contribute in important
ways to the pathogenesis of this disorder (51–56). The
exaggerated production and/or expression of MMPs have
been repeatedly documented in studies of tissues, spu-
tum, BAL fluids, and BAL cells from patients with COPD
(4, 8, 10, 57, 58). Our studies demonstrate that MMP-9
and MMP-12 play crucial roles in the alveolar enlarge-
ment, lung enlargement, enhanced compliance, and even-
tual respiratory failure and death seen in IL-13–overex-
pressing transgene+ mice. They also demonstrate that
MMP-9 and MMP-12 play unique roles in the generation
of the neutrophilic and eosinophil/macrophage–rich
inflammation seen in these animals. These observations
suggest that these MMPs may play similar crucial roles in
the pathogenesis of the alveolar remodeling, inflamma-
tion, and respiratory failure in patients with COPD. As a
consequence, these MMPs are outstanding targets
against which pharmacologic therapies can be directed.
The validation of these targets is an important issue for
COPD, since therapies that intercede in the pathogenet-
ic pathways that destroy lung tissue in this disease do not
exist and our present therapies (bronchodilators and cor-
ticosteroids) do not consistently decrease MMP expres-
sion (59). Therapeutic interventions focused on MMP-9
and/or MMP-12 may also be important in a wide variety
of other pulmonary diseases characterized by exaggerat-
ed MMP and/or IL-13 production, including idiopathic
pulmonary fibrosis, hypersensitivity pneumonitis, lung
cancer, nonspecific interstitial pneumonitis/bronchioli-
tis obliterans organizing pneumonia (NSIP/BOOP), and
silicosis (9, 11, 12, 60).
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